Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists - Heart and Vessels
Source : https://link.springer.com/article/10.1007/s00380-022-02027-w
Although high thromboembolic risk was assumed in elderly patients with heart failure (HF) and atrial fibrillation (AF), inadequate control of prothrombin time/international normalized ratio was often observed in patients using...
Conclusion/Relevance: Compared with VKA therapy, DOAC therapy was associated with lower risk of all-cause mortality in the elderly HF patients with AF and renal dysfunction.
Share
Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35029056/
doi: 10.1002/ehf2.13785. Online ahead of print. 1 Department of Medicine, University of Mississippi, Jackson, MS, USA. 2 Division of Cardiology, Duke University Medical Center, Durham, NC, USA. 3 Division of...
Conclusion: Improvement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality...
Share
Empagliflozin-A New Chance for Patients with Chronic Heart Failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35056104/
The heart failure (HF) epidemic is one of the challenges that has been faced by the healthcare system worldwide for almost 25 years. With an ageing world population and a...
Conclusion/Relevance: In this review we discuss the cardioprotective mechanism of the drug in the context of the benefits of empagliflozin use in patients with chronic cardiac insufficiency. Numerous findings confirm that despite its potential limitations, the use of empagliflozin in HF treatment is advantageous and effective.
Share
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35005582/
doi: 10.1016/j.eclinm.2021.101240. 1 Department of Renal Medicine, Clinical Research Center for Rare Diseases "Aldo and Cele Daccò", Centro Anna Maria Astori (IRCCS), Science and Technology Park Kilometro Rosso, Istituto di...
Interpretation: Our data suggests that empagliflozin might slow kidney function loss and delay the estimated onset of projected ESKD in patients with type 2 diabetes and cardiovascular disease complicated by NRP.
Share
Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35024052/
39-52% of patients with heart failure and reduced ejection fraction in this real-world heart failure population were eligible for SGLT2-inhibitor treatment, corresponding to 11-14% of all heart failure patients. Compared...
Conclusions: 39-52% of patients with heart failure and reduced ejection fraction in this real-world heart failure population were eligible for SGLT2-inhibitor treatment, corresponding to 11-14% of all heart failure patients. Compared to trial participants, eligible real-world patients were significantly older with worse renal function, more...
Share